Bayer’s Stroke Drug Achieves Breakthrough Trial Results, Boosting Market Confidence 
JD.com Pledges 22 Billion Yuan Housing Support for Couriers as China’s Instant Retail Competition Heats Up 
Westpac Director Peter Nash Avoids Major Investor Backlash Amid ASX Scrutiny 
Is space worth the cost? Accounting experts say its value can’t be found in spreadsheets 
FDA Pilot Program Eases Rules for Nicotine Pouch Makers 
Major Drugmakers Slash U.S. Prices and Sell Directly to Patients Amid Trump’s Push for Affordable Medicines 
Novo Nordisk Appoints Greg Miley to Lead Corporate Affairs Amid U.S. Drug Pricing Pressure 
Astronomers have discovered another puzzling interstellar object − this third one is big, bright and fast 
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment 
Nvidia Develops New Location-Verification Technology for AI Chips 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
SpaceX’s Starship Completes 11th Test Flight, Paving Way for Moon and Mars Missions 
Neuren Pharmaceuticals Surges on U.S. Patent Win for Rare Disorder Drug 
Mizuho Raises Broadcom Price Target to $450 on Surging AI Chip Demand 
SpaceX Starship Test Flight Reaches New Heights but Ends in Setback 
Kennedy Sets September Deadline to Uncover Autism Causes Amid Controversy 
Eli Lilly has announced that the U.S. Food and Drug Administration (FDA) has approved its new therapy, Inluriyo, for the treatment of advanced or metastatic breast cancer in adult patients who have already undergone prior therapy. This milestone approval marks a significant advancement in addressing a challenging form of cancer that often resists standard treatments.
Metastatic breast cancer, also known as Stage IV breast cancer, occurs when cancer spreads beyond the breast and nearby lymph nodes to other organs such as the bones, liver, lungs, or brain. Certain breast cancers develop ESR1 mutations, which cause estrogen receptors to become overly active. While these receptors normally regulate cell growth, their mutation can accelerate cancer progression. Inluriyo directly targets these receptors by binding to and breaking them down, effectively blocking their activity to help slow disease progression.
The FDA’s decision was based on data from a late-stage clinical trial showing that patients treated with Inluriyo had a 38% lower risk of disease progression or death compared to those receiving standard therapies. On average, patients taking Inluriyo went 5.5 months without cancer worsening, versus 3.8 months with other treatments.
Inluriyo is an oral therapy recommended at a daily dose of 400 mg—taken as two 200 mg tablets on an empty stomach. The drug will be available in the U.S. within weeks at a list price of $22,500 per 28-day cycle. Eli Lilly highlighted that the medication carries an embryo-fetal toxicity warning, underscoring the risks of exposure during pregnancy.
The company is also investigating Inluriyo in combination with abemaciclib, another Lilly therapy, for advanced breast cancer, as well as in early-stage disease as adjuvant treatment.
With its approval, Inluriyo offers patients with metastatic breast cancer and ESR1 mutations a new, targeted treatment option that could improve outcomes and provide hope in one of the toughest stages of breast cancer.
